EDAP TMS S.A. to Present at Roth Capital Conference in New York

Search Blogs that Mention this News Release
Click this link to view linked Bookmarking Services
Click this link to view linked Blogging Services
EDAP TMS S.A. to Present at Roth Capital Conference in New York
    LYON, France, Aug. 23 /PRNewswire-FirstCall/ -- EDAP TMS S.A. (Nasdaq:
EDAP), the global leader in High Intensity Focused Ultrasound (HIFU)
treatment of prostate cancer, announced management will present at the Roth
Capital Partners New York Conference on September 6, 2006 at the Westin
Time Square Hotel in New York, NY. The company roster will include a
scheduled presentation at 4:00 p.m. Management will also be available to
conduct individual meetings at the conference and in the Midtown New York
area.
    Institutional investors interested in meeting with management should
contact Roth Capital Partners regarding conference meetings or Halliburton
Investor Relations (Matt Kreps, 972-458-8000) for meetings outside the
conference schedule. Information regarding the conference can be found
online at http://www.rothconference.com . The Roth Conference is available
by invitation of Roth Capital Partners only.
    EDAP TMS S.A. provides the Ablatherm-HIFU medical device for the
treatment of localized prostate cancer by High Intensity Focused
Ultrasound. Ablatherm- HIFU is widely regarded as the most advanced and
clinically proven HIFU device for prostate cancer. HIFU therapy is fully
approved in Europe, Canada, Australia and other regions as a noninvasive
therapeutic choice offering patients a high rate of success with low side
effects. The treatment is also proven effective with low side effects for
patients suffering a recurrence of localized prostate cancer after prior
radiation therapy.
    Ablatherm-HIFU therapy is reimbursed in certain markets and the company
continues to seek additional reimbursements. EDAP is presently increasing
its marketing activity in conjunction with its approval for use in key
European markets and a growing clinical interest from the urology community
based on published and peer reviewed studies supporting Ablatherm-HIFU as
an effective and attractive therapeutic choice for nonsurgical patients.
Clinical studies are being conducted in the United States using
Ablatherm-HIFU through EDAP's US partner HealthTronics.
    Information about EDAP and HIFU therapy can be found online at
http://www.edap-tms.com and http://www.hifu-planet.com .
    About EDAP TMS S.A.
    EDAP TMS S.A. develops and markets Ablatherm, the most advanced and
clinically proven choice for High Intensity Focused Ultrasound (HIFU)
treatment of localized prostate cancer. HIFU treatment is shown to be a
minimally invasive and effective treatment option with a low occurrence of
side effects. Ablatherm-HIFU is generally recommended for patients with
localized prostate cancer (stages T1-T2) who are not candidates for surgery
or who prefer an alternative option, or for patients who failed
radiotherapy treatment. The company is also developing this technology for
the potential treatment of certain other types of tumors. EDAP TMS S.A.
also produces and commercializes medical equipment for treatment of urinary
tract stones using Extra-corporeal Shockwave Lithotripsy (ESWL).
    For more information on the Company, contact Halliburton Investor
Relations at (972) 458-8000, the Corporate Investor Relations Dept at +33
(0)4 78 26 40 46 or see the Company's Web sites at http://www.edap-tms.com
and http://www.hifu-planet.com .
    In addition to historical information, this press release contains
forward-looking statements that involve risks and uncertainties. These
include statements regarding the Company's growth and expansion plans. Such
statements are based on management's current expectations and are subject
to a number of uncertainties and risks that could cause actual results to
differ materially from those described in these forward-looking statements.
Factors that may cause such a difference include, but are not limited to,
those described in the Company's filings with the Securities and Exchange
Commission. Ablatherm-HIFU treatment is in clinical trials but not yet FDA
approved or marketed in the United States.
     CONTACT:  EDAP TMS S.A.
               Hugues de Bantel - Philippe Chauveau
               Blandine Confort
               +33 4 78 26 40 46

               Halliburton Investor Relations
               Matt Kreps - Geralyn DeBusk
               972 458 8000
SOURCE EDAP TMS S.A.
http://www.edap-tms.com
http://www.rothconference.com
http://www.hifu-planet.com
CONTACT:
Hugues de Bantel or Philippe Chauveau or
Blandine Confort, all of EDAP TMS S.A., +33-4-78-26-40-46; or
Matt Kreps or Geralyn DeBusk, both of Halliburton Investor
Relations, +1-972-458-8000, for EDAP TMS S.A.